A New Benchmark in Multiple Myeloma Treatment: Two-Year Data on Belamaf-VRd Shows Promise
Nearly 96% of patients with newly diagnosed, transplant-eligible multiple myeloma (NDTE-MM) achieved an objective response when treated with belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd), followed by maintenance therapy. This remarkable figure, stemming from the two-year analysis of the GEM-BELA-VRd clinical trial, presented at the 2025 International Myeloma Society Annual Meeting, signals a potential paradigm shift in how we approach this challenging cancer. The data isn’t just about response rates; it’s about achieving deeper, more durable remissions and, crucially, managing the side effects that often accompany aggressive treatment regimens.
Deep Remissions and the Pursuit of MRD-Negativity
The GEM-BELA-VRd trial (NCT04802356) involved 50 patients with NDTE-MM. The treatment protocol included six cycles of belamaf (2.5 mg/kg) plus VRd, followed by autologous stem cell transplant (ASCT), consolidation with two more cycles of belamaf-VRd, and then continuous lenalidomide maintenance alongside belamaf (1.9 mg/kg Q8W) for up to two years. The results are compelling: an impressive 80% of patients experienced a complete response (CR), and an even higher 88% achieved minimal residual disease (MRD)–negativity. This pursuit of MRD-negativity – meaning no detectable myeloma cells remain – is increasingly recognized as a critical predictor of long-term survival.
Per-protocol analysis further refined these results, showing MRD-negativity rates climbing to 93.9% after two years of maintenance. Importantly, progression was rare, with only three patients experiencing disease progression over the follow-up period (median 40 months). The 3-year time to progression (TTP) stood at an encouraging 93%, while progression-free survival (PFS) reached 78% and overall survival (OS) was 82%. These figures suggest that the belamaf-VRd regimen not only induces deep remissions but also helps to sustain them.
Managing Toxicity: A Key to Long-Term Adherence
One of the biggest hurdles in myeloma treatment is managing side effects. The GEM-BELA-VRd trial acknowledged this, with safety as a primary endpoint. While ocular events (OEs) were observed, they were generally reversible and manageable, with a median recovery time of 75 days. Notably, the frequency of OEs decreased compared to earlier phases of the trial, suggesting that proactive monitoring and management strategies are effective.
Hematological toxicities, such as neutropenia, were also monitored closely. Grade 3 or higher neutropenia occurred in 36% of patients in the first year, decreasing to 22% in the second year, potentially indicating adaptation to the treatment. Infections, a common concern in myeloma patients, occurred in 18% in the first year and 8% in the second. Only four patients discontinued maintenance due to toxicity, demonstrating the overall tolerability of the regimen.
The Impact of COVID-19 and the Future of Frontline Therapy
The trial wasn’t without its challenges. Five patients died from infections, four of which were attributed to COVID-19. This underscores the vulnerability of myeloma patients and the significant impact of external factors, like pandemics, on treatment outcomes. It also highlights the need for robust infection prevention strategies and proactive management of comorbidities.
Looking ahead, the investigators concluded that belamaf-VRd, followed by continuous lenalidomide maintenance, represents a promising approach for NDTE-MM. The data strongly supports further evaluation of belamaf in the frontline setting, potentially as a standard of care. The combination’s ability to induce deep remissions and maintain them over time, coupled with manageable toxicity, positions it as a significant advancement in the field. The ongoing research will likely focus on identifying biomarkers to predict which patients are most likely to benefit from this regimen and optimizing the treatment schedule to further minimize side effects.
Beyond GEM-BELA-VRd: Personalized Approaches and Novel Targets
The success of GEM-BELA-VRd also fuels the broader exploration of antibody-drug conjugates (ADCs) in myeloma. ADCs like belamaf deliver potent chemotherapy directly to myeloma cells, minimizing exposure to healthy tissues. This targeted approach is a key trend in cancer treatment, and we can expect to see more ADCs entering clinical trials in the coming years. Furthermore, the focus is shifting towards personalized medicine, tailoring treatment regimens based on individual patient characteristics and genetic profiles. Understanding the specific mutations driving a patient’s myeloma will be crucial for selecting the most effective therapies. Learn more about Belantamab Mafodotin from the National Cancer Institute.
What are your predictions for the future of multiple myeloma treatment? Share your thoughts in the comments below!
